Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis a vaccine (inactivated, HM175 strain)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Hepatitis a vaccine (inactivated, HM175 strain) is an **inactivated viral vaccine** developed by **GSK** and marketed as **Havrix** for active immunization against hepatitis A virus infection. The vaccine contains **formaldehyde-inactivated hepatitis A virus strain HM175** produced in **MRC-5 human diploid cells**, purified and adsorbed to an aluminum-based adjuvant, and is administered to induce protective anti-HAV antibody responses. It is indicated for prevention of hepatitis A disease in individuals **12 months of age and older**, with marketed pediatric and adult dose strengths, and clinical studies showed high seroconversion after the first dose and protective efficacy of about 95%.
- Brand names
- Havrix
- Other names
- hepatitis a vaccine (inactivated, HM175 strain)inactivated hepatitis a virus vaccinehepatitis a vaccine inactivated
Beyond the preview
Go deeper on hepatitis a vaccine (inactivated, HM175 strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis a vaccine (inactivated, HM175 strain).